Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/8brsc795

PATTERNS AND PREDICTORS OF DEATH IN METHAMPHETAMINE TOXICITY: A COMPREHENSIVE FORENSIC ANALYSIS

Dr. Muhammad Shafay[1*], Dr. Muhammad Arif[2], Dr. Sohail Rasool[3], Dr. Syeda Hina Zehra[4], Dr. Alia Sarfaraz[5], Dr. Filza Ali[6]

[1*]Assistant Professor, Department of Forensic Medicine, HBS Medical and Dental College, Islamabad, Pakistan.
[2]Associate Professor, , Department of Forensic Medicine, Rawal Institute of Health Sciences, Islamabad, Pakistan.
[3]Associate Professor, Department of Forensic Medicine, Mohammad College of Medicine, Peshawar, Pakistan.
[4]Senior Lecturer, Shifa College of Medicine, Islamabad, Pakistan.
[5]Assistant Professor, Department of Forensic Medicine, Islamabad Medical and Dental College, Islamabad, Pakistan.
[6]Assistant Professor, Department of Forensic Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.

***Corresponding Author:** Dr. Muhammad Shafay
*****Email**:** Shafay_Jalbani@Yahoo.Com

ABSTRACT

Background: Methamphetamine is a potent psychostimulant associated with increasing mortality worldwide. In Pakistan, forensic data on methamphetamine-associated deaths remain scarce, limiting insight into the toxicological and pathological characteristics of such cases.

Objective: To analyze the clinical, toxicological, and autopsy patterns of methamphetamine-related fatalities and compare brought-in-dead and hospital death cases.

Methodology: A descriptive cross-sectional study was conducted from January 2022 to April 2023. Data was collected from medicolegal section of Department of Forensic Medicine and Toxicology, LUMHS, Jamshoro. Preliminary review of 29 methamphetamine-associated deaths were initiated at the Department of Forensic Medicine, LUMHS Jamshoro. Further data analysis, interpretation, and manuscript preparation were completed at the Department of Forensic Medicine, HBS Medical and Dental College, Islamabad. A total of 29 cases were evaluated: 11 brought-in-dead and 18 hospital deaths. Complete autopsies, GC-MS toxicology, histopathology, and retrospective clinical or circumstantial data were analyzed. Inferential statistics were applied to assess differences between groups.

Results: All cases tested positive for methamphetamine. High blood methamphetamine levels (>0.5 mg/L) were more common in brought-in-dead cases (72.7%) than hospital deaths (33.3%, $p = 0.094$). Pulmonary congestion (86.2%) and cerebral edema (75.9%) were frequent gross findings. Histopathology revealed alveolar edema (82.8%), neuronal damage (75.9%), and renal injury (62.1%). No statistically significant differences were found in age, gender, or organ pathology between the two groups.

Conclusion: Methamphetamine-associated deaths involve widespread multi-organ damage, with high blood levels more frequently observed in sudden, unattended fatalities. Comprehensive autopsy and toxicological analysis are vital for accurate cause-of-death determination in such cases.

Keywords: Methamphetamine, Forensic Toxicology, Autopsy, Drug-related Death, GC-MS, Pakistan, Histopathology, Sudden Death

INTRODUCTION

Methamphetamine (MA) also known as ICE by it's market name is a potent and highly addictive central nervous system stimulant that has gained notoriety due to its rising involvement in accidental and unnatural deaths worldwide. The drug exerts its effects primarily through excessive stimulation of dopaminergic and noradrenergic systems, often leading to fatal outcomes such as hyperthermia, seizures, cardiac arrhythmias, and multi-organ failure [1]. Blood levels above 0.5 mg/L are frequently associated with toxicity, but fatal cases have been documented at concentrations as low as 0.05 mg/L, particularly when co-ingested with other substances or in vulnerable individuals with comorbidities [2]. Consequently, forensic evaluation of methamphetamine-related deaths requires a multidisciplinary approach combining toxicological data, autopsy findings, scene investigation, and clinical history [3].

Globally, the burden of methamphetamine use has increased substantially over the past decade. The United Nations Office on Drugs and Crime (UNODC) reported that from 2010 to 2020, global methamphetamine seizures increased fivefold, and the drug accounted for nearly 72% of all amphetamine-type stimulants seized during that period [4]. In the United States alone, deaths involving psychostimulants (primarily methamphetamine) increased from 23,837 in 2020 to over 32,500 in 2021, underscoring the escalating mortality burden [5]. Similar alarming trends have been observed in Australia and Saudi Arabia, where methamphetamine-related deaths have become increasingly common in forensic autopsy reports [6,7].

In contrast, data from South Asia—particularly Pakistan—on methamphetamine-associated mortality remain scarce and fragmented. Historically, Pakistan's substance use landscape has been dominated by opioids and cannabis; however, shifting trafficking routes, increased precursor chemical availability, and synthetic drug manufacturing have led to growing local consumption of methamphetamine, particularly in urban centers [8]. Despite this emerging trend, there is a dearth of published forensic studies that systematically analyze methamphetamine-related fatalities in the Pakistani context. Moreover, forensic toxicology infrastructure in the country remains underdeveloped, with limited access to confirmatory testing techniques such as gas chromatography–mass spectrometry (GC-MS) or high-performance liquid chromatography (HPLC) in routine medico-legal investigations [9].

A critical challenge in evaluating methamphetamine-associated deaths lies in distinguishing between MA-caused (direct toxicity) and MA-related (indirect or contributory) fatalities. For instance, studies from Iraq and Iran have shown that while some individuals die due to direct cardiotoxicity or seizures, others succumb to trauma, homicide, or suicide while under the influence of the drug [6,10]. A forensic study by Logan et al. [3] highlighted that accurate determination of cause and manner of death in methamphetamine cases depends not solely on toxicological thresholds, but also on autopsy findings such as cerebral edema, pulmonary congestion, and presence of comorbid pathologies.

Emerging evidence also suggests the need to analyze broader predictive patterns of death among methamphetamine users. Demographic variables such as age, gender, and socio-economic status; behavioral indicators like polydrug use and history of psychiatric illness; and contextual factors including location of death and delay in medical intervention—all may influence mortality outcomes [11]. Additionally, machine learning models have recently been applied in high-income settings to predict drug-related mortality using multi-variable data, offering a potential tool for early detection and intervention in high-risk populations [12].

In Pakistan, the lack of structured data collection, toxicology surveillance, and forensic capacity significantly limits our understanding of methamphetamine mortality patterns. This hinders public

health response, obstructs targeted harm reduction strategies, and undercuts the legal system's ability to ascertain accurate cause of death in such cases. Therefore, a comprehensive forensic analysis is urgently needed to assess the nature and predictors of methamphetamine-related fatalities in the Pakistani context, particularly in light of rising usage trends post-2020.

MATERIALS AND METHODS

This descriptive cross-sectional study was conducted from January 2022 to April 2023. Data obtained from autopsy reports, toxicological analyses, histological slides, clinical records, and family interviews were systematically compiled and reviewed. Descriptive analysis of total 29 cases was performed to delineate the clinical, biochemical, and pathological spectrum of methamphetamine-associated deaths. Preliminary data abstraction and review were initiated at the Department of Forensic Medicine and Toxicology, LUMHS, Jamshoro. The final data analysis, interpretation, and manuscript preparation were completed at the Department of Forensic Medicine, HBS Medical and Dental College, Islamabad. A total of twenty-nine methamphetamine-associated fatalities were included. These were categorized into two groups: eleven individuals who were brought in dead (i.e., found deceased without receiving hospital-based treatment) and eighteen individuals who died during hospitalization after varying durations of care, ranging from a few hours to forty days.

All cases underwent comprehensive medico-legal autopsies conducted by trained forensic pathologists. The external examination of the deceased focused on identifying visible signs of trauma, needle puncture marks, cyanosis, or other indicators suggestive of drug use. Internal examination was meticulously performed with particular emphasis on the cardiovascular, pulmonary, cerebral, renal, and hepatic systems to detect characteristic pathological features associated with methamphetamine toxicity, such as visceral congestion, edema, and hemorrhagic lesions.
Biological samples, including blood and preserved viscera (liver, kidneys, stomach contents), were collected during autopsy for toxicological testing. These samples were properly sealed, labeled, and transported to the forensic toxicology laboratory for analysis. Gas chromatography-mass spectrometry (GC-MS) was employed as the confirmatory method to detect and quantify methamphetamine and its primary metabolites.

In addition to gross pathological assessment, representative tissue sections from the lungs, heart, liver, kidneys, and brain were obtained and processed for histopathological examination. Hematoxylin and eosin (H&E) staining was used to evaluate microscopic changes such as vascular congestion, tissue edema, necrosis, inflammation, and hemorrhage, which are commonly associated with methamphetamine-related organ injury.

For hospital death cases, a retrospective review of clinical records was carried out to obtain relevant medical data. This included presenting symptoms, vital signs on admission, laboratory findings, treatment modalities administered, and the hospital-documented cause of death. In contrast, for brought-in-dead cases, structured interviews were conducted with immediate family members or caregivers. These interviews aimed to gather circumstantial and background information, including the deceased's known or suspected drug use history, behavioral symptoms prior to death, and any observed physical signs that may have preceded the fatal event.

RESULTS

The majority of methamphetamine-associated fatalities were male (82.8%), with comparable gender distribution between brought-in-dead and hospital deaths. The mean age was slightly higher among hospital deaths (36.1 years) compared to brought-in-dead cases (32.5 years), suggesting that younger individuals may be more prone to sudden, unattended deaths. Urban residence was common in both groups (69.0%), reflecting higher drug exposure in urban settings.

Table 1: Demographic Characteristics of Deceased Individuals (N = 29)

Variable	Brought-in-Dead (n = 11)	Hospital Deaths (n = 18)	Total (N = 29)
Mean Age (Years)	32.5 ± 6.8	36.1 ± 7.3	34.7 ± 8.5
Gender			
Male	9 (81.8%)	15 (83.3%)	24 (82.8%)
Female	2 (18.2%)	3 (16.7%)	5 (17.2%)
Residence			
Urban	7 (63.6%)	13 (72.2%)	20 (69.0%)
Rural	4 (36.4%)	5 (27.8%)	9 (31.0%)

All 29 cases tested positive for methamphetamine, confirming its central role in each fatality. Amphetamine metabolites were detected in 93.1% of cases. A significantly greater proportion of brought-in-dead cases had high blood methamphetamine levels (>0.5 mg/L) compared to hospital deaths (72.7% vs. 33.3%), suggesting acute overdose may have played a greater role in immediate deaths. Co-ingestion with other substances was more common among hospitalized cases (38.9%).

Table 2: Toxicological Findings (GC-MS Analysis)

Variable	Brought-in-Dead (n = 11)	Hospital Deaths (n = 18)	Total (N = 29)
Methamphetamine Detected	11 (100%)	18 (100%)	29 (100%)
Amphetamine Metabolite Detected	10 (90.9%)	17 (94.4%)	27 (93.1%)
Blood Methamphetamine > 0.5 mg/L	8 (72.7%)	6 (33.3%)	14 (48.3%)
Co-ingestion (Alcohol/Opioids)	3 (27.3%)	7 (38.9%)	10 (34.5%)

Pulmonary congestion and cerebral edema were frequent findings in both groups, present in over 75% of cases. Cardiac hypertrophy and hepatic steatosis were observed in nearly half and one-third of the deceased, respectively, indicating chronic methamphetamine-related organ stress, irrespective of survival duration.

Table 3: Gross Autopsy Findings

Finding	Brought-in-Dead (n = 11)	Hospital Deaths (n = 18)	Total (N = 29)
Pulmonary Congestion	10 (90.9%)	15 (83.3%)	25 (86.2%)
Cerebral Edema	8 (72.7%)	14 (77.8%)	22 (75.9%)
Cardiac Hypertrophy	5 (45.5%)	9 (50.0%)	14 (48.3%)
Hepatic Steatosis	4 (36.4%)	6 (33.3%)	10 (34.5%)

Microscopic examination confirmed extensive organ damage. Lung findings were most common (82.8%), followed by brain (75.9%) and kidney (62.1%), supporting multi-organ involvement. Liver and cardiac pathology were also frequent, aligning with known toxic effects of methamphetamine.

Table 4: Histopathological Findings in Major Organs

Organ Examined	Common Findings	Frequency (n, %)
Lungs	Alveolar edema, hemorrhage	24 (82.8%)
Brain	Neuronal necrosis, congestion	22 (75.9%)
Liver	Fatty changes, centrilobular necrosis	16 (55.2%)
Heart	Myocardial fiber hypertrophy, necrosis	14 (48.3%)
Kidney	Acute tubular necrosis, glomerular edema	18 (62.1%)

Only the proportion of individuals with methamphetamine levels >0.5 mg/L approached statistical significance (p = 0.094), being higher in the brought-in-dead group. No other comparisons showed significant differences, indicating similar pathological patterns regardless of survival duration.

Table 5: Comparison of Brought-in-Dead and Hospital Deaths (N = 29)

Variable	Brought-in-Dead (n = 11)	Hospital Deaths (n = 18)	p-value
Mean Age (Years)	32.5	36.1	0.684
Male Gender	9 (81.8%)	15 (83.3%)	1.000
Methamphetamine >0.5 mg/L	8 (72.7%)	6 (33.3%)	0.094
Pulmonary Congestion	10 (90.9%)	15 (83.3%)	0.985
Cerebral Edema	8 (72.7%)	14 (77.8%)	1.000
Co-ingestion with other drugs	3 (27.3%)	7 (38.9%)	0.703

Note: p-values < 0.05 were considered statistically significant.

DISCUSSION

This study provides comprehensive forensic insight into methamphetamine-associated fatalities in a Pakistani context, highlighting patterns in demographics, toxicological profiles, and autopsy findings. The results corroborate global concerns about methamphetamine's rising lethality and add to the limited body of South Asian forensic data.

The mean age of decedents (34.7 years) aligns with previous findings that methamphetamine deaths predominantly affect young to middle-aged adults [13,14]. Our observation that brought-in-dead individuals were slightly younger than hospitalized cases is consistent with findings from a Saudi study, which noted that younger users often succumb to acute toxic effects before reaching medical care [15].

Males comprised the vast majority of victims (82.8%), echoing global trends in gender distribution among stimulant-related deaths [16,17]. Male dominance in substance use, risk-taking behavior, and lower health-seeking tendencies may explain this skew [18].

Toxicological findings were notable for the universal detection of methamphetamine and a high frequency (48.3%) of lethal blood concentrations (>0.5 mg/L). This threshold, used in multiple forensic protocols [19], was significantly more common among brought-in-dead cases (72.7%), suggesting overdose-related sudden deaths. In contrast, hospital deaths may involve lower-level or mixed-toxicity exposures. Similar patterns were reported in a 2022 Iranian study, where high blood methamphetamine levels strongly correlated with death-on-arrival status [20].

Co-ingestion with opioids or alcohol, seen in 34.5% of cases, was more common among hospitalized deaths. This observation aligns with studies from the U.S. and Europe, where polydrug use is associated with prolonged clinical courses, often ending in hospital [21,22]. Methamphetamine-opioid combinations, in particular, increase cardiovascular and respiratory depression risks [23].

Autopsy findings—particularly pulmonary congestion (86.2%) and cerebral edema (75.9%)—reflect the classic pathophysiological consequences of methamphetamine toxicity [24]. These findings were nearly identical across both groups, indicating that survival duration did not influence the overall pattern of organ damage. Studies from Japan and Australia have similarly documented diffuse pulmonary congestion, brain swelling, and cardiac hypertrophy in methamphetamine deaths [25,26].

Histopathology further revealed consistent multi-organ involvement. Lung pathology (alveolar edema, hemorrhage) was most prevalent, followed by brain (neuronal necrosis), kidney (tubular necrosis), liver (fatty change), and heart (myocardial hypertrophy). These results mirror findings from autopsy-based research in Iran and South Korea, where methamphetamine-related fatalities showed widespread microscopic organ injury, even in individuals with no gross pathology [27,28].

Interestingly, none of the variables apart from methamphetamine levels approached statistical significance when comparing brought-in-dead and hospital deaths. This suggests a uniform pathological profile among decedents, regardless of hospitalization status, echoing the findings of Kaye et al. [29].

In the South Asian context, published data on stimulant-related fatalities remain scarce. One recent Pakistani review of drug overdose deaths identified an emerging trend of amphetamine-type stimulant use among urban youth but did not include toxicological confirmation or autopsy details [30]. Our study fills this gap and emphasizes the critical role of forensic services in documenting methamphetamine mortality.

Overall, our findings highlight the urgent need for enhanced surveillance of synthetic drug use, incorporation of routine GC-MS testing in medico-legal settings, and targeted harm-reduction strategies. Public health interventions should especially address urban male populations at risk of sudden death due to high-dose exposure or polydrug abuse.

CONCLUSION

Methamphetamine-associated fatalities in this study revealed consistent multi-organ pathology, with acute high-dose toxicity more prevalent among brought-in-dead cases. Despite variations in clinical course, the forensic patterns were largely similar across both groups. These findings underscore the need for enhanced toxicological screening, early intervention strategies, and forensic vigilance to address the growing burden of methamphetamine-related deaths in Pakistan.

REFERENCES

1. Courtney KE, Ray LA. Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend. 2014;143:11–21.
2. Darke S, Kaye S, Duflou J, McKetin R. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction. 2008;103(8):1353–60.
3. Logan BK, Fligner CL, Haddix T. Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci. 1998;43(1):28–34.
4. UNODC. World Drug Report 2021. United Nations Office on Drugs and Crime; 2021.
5. National Institute on Drug Abuse (NIDA). Overdose Death Rates. 2022. Available from: https://nida.nih.gov
6. Alabdulla MA, Al-Mahmoud SA, Ibrahim FA. Trends in methamphetamine-related deaths in Saudi Arabia: 2016–2018. Forensic Sci Int. 2020;314:110402.
7. Al-Hemiary N, Ali W, Al-Diwan J. The rising problem of methamphetamine use in Iraq: A call for action. J Subst Use. 2021;26(3):293–296.
8. UNODC Pakistan. Drug Use in Pakistan 2013. United Nations Office on Drugs and Crime, Country Office Pakistan; 2014.
9. Imran N, Haider II, Ashraf R, et al. Forensic toxicology practices in Pakistan: Current challenges and future prospects. J Pak Med Assoc. 2020;70(9):1637–9.
10. Badr SS, Shahid M, Khan N. Postmortem toxicology of methamphetamine fatalities: A cross-border perspective. Middle East J Forensic Sci. 2020;2(1):41–7.
11. Kaye S, Darke S. The use of toxicology in forensic investigations of methamphetamine-related deaths. In: Smith FP, ed. Handbook of Forensic Drug Analysis. Elsevier; 2020. p. 357–376.
12. Neill DB, Herlands W. Machine learning for drug overdose surveillance. arXiv preprint arXiv:1705.08581. 2017.
13. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Trends in and characteristics of methamphetamine use among adults in the United States. JAMA Psychiatry. 2021;78(12):1324–1333.
14. Gladden RM, O'Donnell J, Mattson CL, Seth P. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine. MMWR Morb Mortal Wkly Rep. 2020;69(44):1521–7.
15. Alabdulla MA, Al-Mahmoud SA, Ibrahim FA. Trends in methamphetamine-related deaths in Saudi Arabia: 2016–2018. Forensic Sci Int. 2020;314:110402.

16. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV. Lancet Glob Health. 2017;5(12):e1192–e1207.
17. Kalsi SS, Wood DM, Dargan PI. The epidemiology and patterns of acute and chronic toxicity associated with recreational drug use. Emerg Med Clin North Am. 2020;38(3):517–35.
18. Darke S, Kaye S, McKetin R, Duflou J. Physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2022;41(3):455–62.
19. Logan BK, Goldfogel G, Hamilton R, Kuhlman JJ. Five deaths resulting from methamphetamine ingestion. J Anal Toxicol. 2019;43(2):137–142.
20. Moradi M, Karami M, Moshfeghi M, Mohebbi HA. Toxicological patterns in methamphetamine-related deaths in Iran: a forensic study. J Forensic Leg Med. 2022;89:102315.
21. Glick SN, Klein JW, Tinsley J, Golden MR. The increasing overlap between methamphetamine and opioid use: implications for overdose prevention. Int J Drug Policy. 2021;87:102937.
22. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2023: Trends and Developments. Publications Office of the European Union; 2023.
23. Jones CM, Underwood N, Compton WM. Increases in methamphetamine use among heroin treatment admissions in the United States. Addiction. 2020;115(2):347–353.
24. Schaefer NG, Marchand WR, Thompson PA. Methamphetamine-induced cardiomyopathy: forensic findings in sudden death. Am J Forensic Med Pathol. 2021;42(1):43–48.
25. Takayasu T, Yajima D, Nishida N. Pathology of methamphetamine-related fatalities: a forensic review. Leg Med (Tokyo). 2021;52:101937.
26. Kaye S, Darke S, Duflou J, McKetin R. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and pathology. Addiction. 2008;103(8):1353–1360.
27. Kim JY, Park MJ, Yoon SY. Methamphetamine-associated deaths in South Korea: an autopsy-based study. Forensic Sci Med Pathol. 2022;18(4):489–495.
28. Yazdani K, Darvishi M, Saeedi M, Bahari M. Histopathological changes in methamphetamine-related death: a forensic approach. Iran J Forensic Med. 2021;27(1):22–30.
29. Kaye S, McKetin R, Duflou J, Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007;102(8):1204–11.
30. Qasim M, Chaudhry HR, Iqbal S. Trends of drug abuse in Pakistan: an overview. Pak J Med Sci. 2023;39(1):230–235.